盛夏晚晴天吻戏在第几集,暴躁老妈46集免费看电视剧 ,大雄的秘密道具博物馆国语

伊諾特森

NMR下載 COA and HPLC MSDS下載
names：
Inotersen
CAS號：
1492984-65-2
MDL Number：
MF(分子式)： MW(分子量)：
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
DBK502199-500mg	500mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00
DBK502199-100mg	100mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	伊諾特森
英文別名	Inotersen
CAS號	1492984-65-2
Inchi
InchiKey
分子式 Formula
分子量 Molecular Weight
溶解度Solubility
性狀	Solid
儲藏條件 Storage conditions

伊諾特森使用注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害。
3.取樣品的移液槍頭需及時更換，必要時為避免交叉污染盡可能選擇濾芯吸頭。
4.稱量藥品時選用稱量紙，并無風處取藥和稱量以免揚撒，試劑的容器使用前務必確保干凈，并消毒。
5.取藥品時盡量采用多個藥勺分別使用，使用后清洗干凈。
6.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染。
大規格定制：定制產品請將信息發送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

產品說明	Tropomysoin Receptor Kinases (TRK) like TRKA, TRKB, and TRKC elicit activities that regulate the natural growth, differentiation, and survival of neurons when they interact with endogenous neutrotrophin ligands1,2,3,4,5. TRKA, TRKB, and TRKC are themselves encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively1,2,3,4,5. It has been discovered that chromosomal rearrangements involving in-frame fusions of these genes with various partners, translocations in the TRK kinase domains, mutations in the TRK ligand-binding site, amplifications of NTRK, or the expression of TRK splice variants can result in constitutively-activated chimeric TRK fusion proteins that can act as oncogenic drivers that promote cell proliferation and survival in tumor cell lines1,2,3,4,5,Label.Subsequently, larotrectinib functions as an inhibitor of TRKs including TRKA, B, and C1,2,3,4,5,Label. In in vitro and in vivo tumor models, larotrectinib demonstrated anti-tumor activity in cells with constitutive activation of TRK proteins resulting from gene fusions, deletion of a protein regulatory domain, or in cells with TRK protein overexpression1,2,3,4,5,Label. Larotrectinib had minimal activity in cell lines with point mutations in the TRKA kinase domain, including the clinically identified acquired resistance mutation, G595RLabel. Point mutations in the TRKC kinase domain with clinically identified acquired resistance to larotrectinib include G623R, G696A, and F617LLabel.TargetActionsOrganismAHigh affinity nerve growth factor receptorinhibitorHumansABDNF/NT-3 growth factors receptorinhibitorHumansANT-3 growth factor receptorinhibitorHumans
Introduction
Application1
Application2
Application3